Mika Hilvo

Zora Biosciences (Finland)

Papers

1

Total Citations

157

H-Index

1

About

Dr. Mika Hilvo is a leading researcher in lipidomics and cardiovascular disease, whose work has fundamentally advanced the understanding of how molecular lipid species can predict clinical outcomes. His primary research focuses on the identification and validation of lipid-based biomarkers for coronary artery disease (CAD) and other metabolic disorders. In his landmark 2018 study, which has garnered 157 citations, Dr. Hilvo demonstrated that specific plasma concentrations of molecular lipid species and ceramide ratios are powerful predictors of long-term clinical outcomes in CAD patients. By analyzing data from 581 patients over a median follow-up of nearly five years, he showed that these lipid signatures could forecast major adverse cardiac events with remarkable accuracy. This work has been pivotal in moving beyond traditional cholesterol metrics toward more precise, molecular-level risk stratification. Dr. Hilvo’s contributions have not only deepened the mechanistic understanding of lipid metabolism in heart disease but also provided clinicians with actionable tools for personalized patient management, solidifying his reputation as a key innovator in translational lipidomics.

Research Focus

Key Achievements

1
H-Index
1
Papers
157
Total Citations
157
Avg Citations/Paper
🏆 Most Cited Paper
Plasma concentrations of molecular lipid species predict long-term clinical outcome in coronary artery disease patients
157 citations · 2018
📈 Most Prolific Year: 2018 (1 Papers)
🤝 Key Collaborators: 10
🏛 Institutions: Zora Biosciences (Finland)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago